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Abstract
Background: Contrast-induced nephropathy (CIN), an acute kidney injury resulting from the administration of intravascular
iodinated contrast media, is a significant cause of morbidity/mortality following coronary angiographic procedures in high-risk
patients. Despite preventative measures intended to mitigate the risk of CIN, there remains a need for novel effective treatments.
Evidence suggests that delivery of nitric oxide (NO) through chemical reduction of inorganic nitrate to NO may offer a novel
therapeutic strategy to reduce CIN and thus preserve long term renal function. Design: The NITRATE-CIN trial is a single-
center, randomized, double-blind placebo-controlled trial, which plans to recruit 640 patients presenting with acute coronary
syndromes (ACS) who are at risk of CIN. Patients will be randomized to either inorganic nitrate therapy (capsules containing 12
mmol KNO3) or placebo capsules containing potassium chloride (KCl) daily for 5 days. The primary endpoint is development of
CIN using the Kidney Disease Improving Global Outcomes (KDIGO) criteria. A key secondary endpoint is renal function over a
3-month follow-up period. Additional secondary endpoints include serum renal biomarkers (e.g. neutrophil gelatinase-associated
lipocalin) at 6 h, 48 h and 3 months following administration of contrast. Cost-effectiveness of inorganic nitrate therapy will also be
evaluated. Summary: This study is designed to investigate the hypothesis that inorganic nitrate treatment decreases the rate of
CIN as part of semi-emergent coronary angiography for ACS. Inorganic nitrate is a simple and easy to administer intervention that
may prove useful in prevention of CIN in at-risk patients undergoing coronary angiographic procedures.
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Contrast-induced nephropathy (CIN) refers to a form of acute
kidney injury (AKI) that occurs after parenteral administration
of radiopaque contrast agent. It is the 3rd most common cause
of hospital-acquired renal failure, after decreased renal perfu-
sion and use of nephrotoxic medications1 and remains a major
unmet clinical need. CIN is associated with a prolonged hos-
pital stay, higher hospitalization costs, and a significant
increase in morbidity and mortality.2,3
CIN is commonly seen following procedures for acute cor-
onary syndromes (ACS) with rates 3-5 times higher compared
to elective procedures, with reported incidence ranging from
5%-55%, dependent upon the criteria used for diagnosis, the
clinical setting and the investigated population.4-8 Addition-
ally, emerging evidence suggests that 15%-20% of patients
who do not fulfill the current serum-creatinine-based consensus
criteria for AKI are nevertheless likely to have acute tubular
damage (that can be identified by raised serum biomarkers of
renal injury including neutrophil gelatinase-associated lipoca-
lin (NGAL), cystatin-C, and interleukin-18 (IL-18)) and may
also benefit from therapies targeting CIN.9
Whist the pathophysiology of CIN is not yet fully under-
stood, an important mechanism thought to underlie the condi-
tion is the production of reactive oxygen species (ROS) and
consequent vasoconstrictive renal hypoxic injury.10,11 One of
the likely mechanisms of this is decreased levels of nitric oxide
(NO) as a consequence of NO synthase dysfunction and NO
scavenging.12,13 Thus, strategies that offer a mode of replace-
ment of this “lost” NO represent an approach that may confer
therapeutic benefit.
A potential solution for elevating endogenous NO levels lies
in the non-canonical pathway for NO generation,14 whereby
inorganic nitrate (NO3
) undergoes reduction to nitrite (NO2
)
and then NO in the body. Furthermore, supplementation of
NO3
 through the diet (e.g. green leafy vegetables or beetroot)
or via administration of the anion in the form of a salt,15 deli-
vers NO2
 into the circulation that is then reduced to NO at
sites of need through the activity of specific NO2

reductases.14
Limited data16 exists assessing the effect of NO on CIN,
especially in patients undergoing percutaneous coronary inter-
vention (PCI). In one small study, post-procedural renal func-
tion was compared between 112 patients who received an
organic nitrate prior to PCI and 87 who did not. In those receiv-
ing the organic nitrate, 15.2% developed renal impairment
compared to 29.9% in those who did not (OR: 0.42, 95% CI
0.21-0.84, P ¼ .014). Multivariate logistic regression demon-
strated use of organic nitrate was independently correlated with
a reduction in the development of CIN (OR ¼ 0.33, 95% CI
0.16-0.71, P¼ .004). In the NITRITE-AMI study17 we showed
that a single bolus of intracoronary NO2
 given during primary
PCI for ST-elevation MI led to a significant rise in circulating
NO2
 levels. Additionally, during the first 48 hours after reper-
fusion, 5 patients (12.5%) in the control group developed CIN,
which contrasted with only 1 patient (2.5%) in the NO2

treated group. Further analysis indicated a statistically signifi-
cant difference in the change in creatinine from baseline to 48
hours between the 2 groups (NO2
 group: 4.4 + 3.6 mmol/L
vs Placebo: 9.5 + 3.7 mmol/L, P ¼ .015), and lower levels of
NGAL at 4 hours (105.7 + 46.7 ng/mL vs 76.7 + 31.9 ng/mL,
P¼ .0018) and Cystatin C at 24 hours (1093 + 324.1 pg/mL vs
950 + 182.4 pg/mL, P  .0001) in the NO2 treated group
suggesting reduced rates of subclinical CIN.17 This small phase
II study and the pre-clinical data highlight the potential use of
inorganic NO3
 in this group.
While these studies are encouraging there are limitations
with either approach. It is well accepted that continuous/
repeated administration of an organic nitrate is of limited ben-
efit due to the development of tolerance18 and that raising
circulating levels of inorganic NO2
 with a NO2
 salt is
impacted by issues of toxicity.19 We hypothesize that a safe
NO-delivery approach, without issues of tolerance, is inorganic
NO3
; and this forms the basis for the study described below.
Methods
Study Hypothesis
The primary hypothesis to be tested is whether inorganic NO3

therapy decreases the rate of CIN arising from the administra-
tion of iodinated contrast as part of semi-emergent coronary
angiography for non-ST elevation ACS (NSTE-ACS). In addi-
tion to this, we are testing whether the levels of renal biomar-
kers are proportional to the increase in creatinine arising from
the administration of iodinated contrast and can therefore pre-
dict the occurrence of CIN.
Aims
The main aim of this project is to improve renal outcomes after
angiography for NSTE-ACS, determining whether CIN can be
predicted using novel biomarkers and prevented by prior treat-
ment with inorganic NO3
.
Study Design
This is a randomized, single-center, double-blind placebo-
controlled trial testing the impact of potassium nitrate (KNO3)
capsules versus potassium chloride (KCl) capsule placebo
control.
Study Population
Patients presenting with NSTE-ACS undergoing invasive cor-
onary procedures that involve the administration of intracor-
onary iodinated contrast media (angiography þ/-PCI) that
require CIN prophylaxis will be recruited to the study. These
patients will be recruited at The Barts Heart Centre, based at St
Bartholomew’s Hospital. This is the largest cardiac center in
the UK, serving a population of approximately 6 million people
from North East and Central London and is a 24/7 center per-
forming approximately 6000 angiograms and 2000 non-
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primary angioplasties a year. A total of 640 patients (male and
female, aged 18) undergoing angiography for NSTE-ACS
who require CIN prophylaxis as per local guidelines will be
recruited. See Table 1 for full inclusion and exclusion criteria.
Intervention
Patients will be randomized to receive KNO3 capsules (12
mmol giving 744 mg of NO3
) or an equivalent dose (12
mmol) of KCl as placebo control. The capsules will be taken
by the patient prior to their coronary angiogram procedure and
they will receive a daily dose for 4 days post procedure (5 doses
in total). A previous study from our group20 confirms tolerabil-
ity of KNO3 with minimal side effects. In this study, we also
demonstrated that the levels of circulating NO2
 achieved with
a 12 mmol KNO3 dose were approximately 1.0 mmol/L, a level
that persisted for up to 3 hours following ingestion. In contrast,
a lower dose of 4 mmol did not achieve these levels (rising to
no more than 0.5 mmol/L). In the NITRITE AMI trial, where a
reduction of CIN events appeared to occur, the levels of circu-
lating NO2
 were 0.67 + 0.18 mmol/L.17 Thus, we used a 12
mmol dose for this study to ensure sufficient efficacious levels
of the anion are achieved. The KNO3 and matching KCl pla-
cebo capsules will be supplied by the Pharmacy Manufacturing
Unit based at Guy’s and St Thomas’ NHS Foundation Trust
(GSTT). GSTT Pharmaceuticals hold a license with the
MHRA, which allows the manufacture, storage and distribution
of a range of Sterile and Non Sterile Investigational Medical
Products (IMPs) for Phase I, II, III and IV clinical trials.
Randomization
Patients will be block randomized on a 1:1 basis to receive
either KNO3 capsules or placebo KCl capsules using an algo-
rithm written in a statistical package with a reliable pseudoran-
dom number generator, and stratified by diabetes status. Block
lengths will be varied randomly.
Blinding
Treatment assignment in both the intervention and placebo
groups will remain blinded until data lock and statistical anal-
ysis at the end of the study.
Study Endpoints
The primary endpoints are:
1. Incidence of CIN, as defined by the Kidney Disease
Improving Global Outcomes (KDIGO) criteria for acute
kidney injury.21
The secondary endpoints are:
1. To determine if inorganic NO3
 reduces renal adverse
events including long-term renal impairment caused by
CIN, need for hemofiltration or hemodialysis.
2. To determine whether levels of serum biomarkers
released secondary to renal injury can predict CIN.
3. To determine if inorganic NO3
 ingestion decreases
renal injury as assessed by serum levels of renal
biomarkers.
4. To determine if inorganic NO3
 ingestion decreases
rates of post-procedural MI (Society for Cardiovascular
Angiography and Intervention definition).
5. Assessment of cost effectiveness of inorganic NO3

(Quality-adjusted Life Years [QALYs]) measured over
12 months of follow-up.
6. Assessment of cardiovascular endpoints (Major Adverse
Cardiac Events [MACE]) including death, non-fatal MI,
and unscheduled revascularization.
Experimental Protocol
Patients will be approached on their arrival to Barts Heart
Centre. Following consent, and prior to angiography, up to
40 mL of venous blood will be taken. This sample will be used
to measure baseline renal function, inflammatory markers
(including hs-CRP), renal biomarkers, and baseline plasma
NO3
/ NO2
 (collectively referred to as NOx) levels. Where
possible, urine and saliva samples will also be taken for
Table 1. Inclusion and Exclusion Criteria of NITRATE-CIN Study.
Inclusion Criteria
1. Patients undergoing coronary angiographyþ/-PCI for NSTE-ACS
2. Requirement for CIN prophylaxis as per Barts Heart Centre
Criteria for CIN prophylaxis:
 eGFR <60 mL/min OR
 2 of the following: diabetes, liver failure (cirrhosis), age > 70
yr, exposure to contrast in last 7 days, heart failure (or LVEF
< 40%), concomitant renally active drugs (ACEi, ARB,
NSAIDs, aminoglycosides, diuretics)
3. Aged 18
4. Patients able and willing to give their written informed consent.
Exclusion Criteria
1. ST segment elevation myocardial infarction undergoing Primary
PCI.
2. Patients with eGFR<20 mL/min or on renal replacement therapy
3. Subjects presenting with cardiogenic shock (systolic blood
pressure <80 mmHg for >30 minutes, or requiring inotropes or
emergency intra aortic balloon pump for hypotension treatment)
or cardiopulmonary resuscitation
4. Current life-threatening condition other than vascular disease
that may prevent a subject completing the study.
5. Use of an investigational device or investigational drug within 30
days or 5 half-lives (whichever is the longer) preceding the first
dose of study medication.
6. Patients considered unsuitable to participate by the research team
(e.g., due to medical reasons, laboratory abnormalities, or
subject’s unwillingness to comply with all study related
procedures).
7. Severe acute infection
8. Pregnancy. This will be tested by urine HcG measurement
9. Any Inclusion Criteria not met
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analysis of NOx levels, renal biomarkers and NO3
 reducing
bacteria.
The participant will then be randomized to daily ingestion of
either KNO3 or KCl capsules (placebo). This will be com-
menced prior to their scheduled angiogram and continue daily
(2 capsules) for 5 days. A quality of life assessment (EQ5D)
will be performed prior to PCI (and study drug administration).
EQ5D is an instrument, which evaluates the generic quality of
life that was developed in Europe and is widely used. The
EQ5D descriptive system is a preference-based HRQL measure
with one question for each of the 5 dimensions that include
mobility, self-care, usual activities, pain/discomfort, and anxi-
ety/depression.
Following the angiogram þ/ PCI procedure a blood sam-
ple will be collected 4-6 hours later for renal biomarkers,
inflammatory markers and troponin (if PCI performed) assess-
ment, along with urine and saliva sample collection. At 48-72
hours a blood sample for renal function will be taken, along
with urine and saliva sample collection where possible. The
participant will be asked to return to the clinical center at 3
months for review. At this stage venous blood and urine sam-
ples will be collected as well as EQ5D and assessment for
MACE. After 1 year, the participant will be contacted by tele-
phone for assessment of MACE and EQ5D. The whole duration
of the study will be 1 year for each participant (see Figure 1).
Participants have no obligation to complete the whole study
and are free to withdraw at any point.
Blood, Saliva and Urine Analysis
U&E and hs-CRP sample analysis will be performed at the
local Barts Health Biochemistry laboratory. Blood samples will
be taken from the venous side of the circulation from a hand
vein using a yellow butterfly needle (19 gauge). Blood samples
will be centrifuged immediately for plasma, and samples stored
at 80 C for the purposes of making biochemical measure-
ments (e.g. NOx/cGMP). All samples will be discarded once
used as per local procedures. Saliva and urine will be collected
in a falcon tube at the time of visits and stored for analysis.
Saliva will be centrifuged and a pellet generated. This pellet
contains oral bacteria that have dislodged from the oral cavity.
This pellet will be frozen (80 C) until identification of the
oral microbiota by second-generation genome sequencing.
NOx concentrations in saliva, blood and urine will be deter-
mined using the technique of chemiluminescence, which will
be performed at The William Harvey Research Institute
(WHRI), Queen Mary University of London (QMUL) and
measured at baseline, 4-6 hours, 48-72 hours, and at 3 months.
Measures of renal biomarkers (serum and urine) will be con-
ducted at WHRI (QMUL). These will also be measured at
baseline, 4-6 hours, and at 48-72 hours.
Management
This study is supported by the Barts Cardiovascular Clinical
Trials Unit (CVCTU), a branch of the Barts CTU UKCRC Reg
No. 4. The CVCTU will oversee the management and conduct
of the trial, including safety reporting, coordination of trial
committees, statistical analysis and reporting, and database
management and electronic case report form (e-CRF) design.
Data will be captured in REDCap, a web-based electronic
database, for all study participants and the database will be
held on a secure server at QMUL. Participants eligible for the
study will be given a screening number, and this number will
be used to identify them throughout their study duration. The
screening number will be identified on all e-CRFs and study
documentation, e.g. questionnaires, lab reports. Only autho-
rized users approved by the Chief Investigator (CI) will have
access to the REDCap electronic database, and each user will
be assigned specific user roles and rights. Sponsor represen-
tatives and CVCTU team members will have read-only access
to the data. The study Research Nurse will be the primary
person with delegated responsibility for data entry and eCRF
completion.
Adverse Events Reporting
All adverse events (AEs) and serious AEs will be recorded and
reported to the principal investigator (PI). Related unexpected
serious AEs, as assessed by the PI, will be reported within 24
hours of the research team becoming aware, to the Joint
Research Management Office and the main Research Ethics
Committee.
Monitoring
A Trial Steering Committee composed of 3 independent
experts in the fields of nephrology, interventional cardiology
and clinical trials along with the investigators and 1-2 lay
members will monitor the study. They will meet before patient
recruitment and 6 monthly thereafter to assess trial conduct,
recruitment, feasibility or other arising issues. An independent
Data and Safety Monitoring Board (DSMB) will be formed to
monitor patient safety. The DSMB will meet prior to initiation
of the study, after recruitment of 10 patients, and thereafter at 6
monthly intervals. If there is serious concern with the safety of
the participants the DSMB may recommend early termination
of the study.
Statistical Analysis
The reported incidence of ACS-associated AKI is extremely
heterogeneous, ranging from 5% to 55%, and it varies with the
criteria used for diagnosing AKI, the clinical setting and the
investigated population.4,5 The most recent data from the Acute
Coronary Treatment and Intervention Outcomes Network
(ACTION) registry demonstrated that AKI occurred in 16%
of 59 970 patients with acute myocardial infarction (AMI),6
with similar studies showing rates of 15% according to RIFLE
criteria and 13% according to AKIN criteria in patients with
AMI.7 These data were recently confirmed in the large-scale
Harmonizing Outcomes With Revascularization and Stents in
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Acute Myocardial Infarction (HORIZONS-AMI) trial, which
reported AKI in 16% of the patients.8 For our study calcula-
tions, we therefore propose a conservative CIN incidence of
12%. Our preliminary data17 demonstrated an 80%-related
reduction in CIN. For our power calculations, we have pro-
posed an effect at the lower end of this range and have powered
the study to determine a difference of 60%. For a power of 80%
and a significance level of 0.05, we need to recruit 232 patients
into each trial arm, 464 patients in total, allowing for 27.5%
drop out (primary endpoint) this means 320 patients in each
arm and a total study population of 640 ACS patients. Sub-
group analysis of the primary endpoint will be presented as
unadjusted effect sizes by subgroup and for all patients using
a modified forest plot, along with a test for heterogeneity.
Subgroups will provide insight into the following mechanistic
and exploratory questions.
Figure 1. Study flowchart. NSTEACS: Non-ST segment elevation acute coronary syndrome; PCI: percutaneous intervention; CIN: contrast
induced nephropathy; ESRF: end-stage renal failure; STEMI: ST segment elevation myocardial infarction; U&E: urea and electrolytes; NOx: nitric
oxide levels (NO2/ NO3); MACE: major adverse cardiac events; EQ5D: quality of life questionnaire.
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1. Pre-existing nitrate use versus no prior use: Do
patients already established on an organic nitrate derive
similar benefits from inorganic nitrate therapy after an
ACS? Previous studies have suggested less effect in
patients established on organic nitrates.
2. Diabetic versus non-diabetic patients: Is dietary
nitrate equally effective in diabetic and non-diabetic
patients? Previous studies have suggested less benefit
of nitrate in patients with diabetes.
3. Troponin positive versus troponin negative: Is the
risk of CIN higher and dietary nitrate more effective
in patients with evidence of myocardial infarct (troponin
positive (NSTEMI) rather than troponin negative
(unstable angina)).
4. Mehran risk score group (low, moderate etc): Is the
benefit of inorganic nitrate seen throughout patients of
varying CIN risk or is it only beneficial in those at the
highest risk (Mehran score 11-15/ 16)?
Economic Analysis
Economic evaluation will assist policy makers to decide
whether inorganic NO3
 represents an efficient use of NHS
resources. Cost-effectiveness analysis will be used to estimate
the incremental costs and QALYs. Incremental cost per QALY
gained by using inorganic NO3
 compared to standard care
will be estimated by calculating the area under the curve for
health utility using the EQ5D and health service costs up to 12
months. Quality of life and symptoms will be measured using
the EQ5D questionnaires at baseline, 3 and 12 months after
index admission. All health care consumption and costs will
be estimated from a health system (NHS) perspective using
patient self-reported questionnaires, and from hospital records.
Costs will be attributed to the need for (i) continued hospitali-
zation, (ii) procedural complications, and (iii) rehospitalization
for renal dysfunction or myocardial ischemia. Costs of hospital
admission will be measured using a top-down costing strategy.
These costs will be measured for each patient in the trial and
extrapolated to the general population to provide the estimated
cost per patient.
Summary
The NITRATE-CIN study is a proof-of- concept single-center,
randomized, placebo-controlled, clinical trial designed to
ascertain whether use of inorganic NO3
 might prove useful
adjunctive therapy in improving renal function, reducing CIN
and improving outcomes in ACS patients undergoing angiogra-
phy þ/ PCI.
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